The image shown is for illustrative purposes only and does not represent the actual appearance of your specific compounded medication.
Olympus
Olympus contains a combination of two medications designed to enhance sexual arousal, increase sensitivity, boost energy, and intensify pleasure. This compounded formulation may also help address issues with low libido and reduce anxiety related to sexual performance.
Bremelanotide
- Nonselective melanocortin receptor (MCR) agonist
Oxytocin
- The "Love" hormone
Suggested Dosing
Olympus (Bremelanotide/Oxytocin) 1 mg/20IU Sublingual Flex-Dose Tablet
Dissolve 1/4-1 tablet sublingually 30 minutes prior to sexual activity as directed by your provider.
IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS
This medication has been compounded (custom-prepared) by a pharmacy. Compounded medications are specially prepared for individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.
This compounded preparation:
- Has not been approved by the FDA
- Has not undergone FDA review for safety, effectiveness, or quality
- Is prepared specifically for you based on your prescriber's order
- Individual outcomes may vary
Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions. Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications. This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.
This compounded medication is only available when the commercially available product is unavailable or when a prescriber determines that there is a clinically significant difference for the patient.
Medicine Information
Potential benefits
- Supports libido1, 5
- Aids in sexual receptivity1
- Formulated to support rapid onset of arousal1, 4
- Promotes erection quality and sensitivity1
- May help address premature ejaculation1, 3
- Flexible dosing options for varied lifestyles
Adverse Effects
- Nausea6,7
- Flushing7
- Headache7
- Dizziness7
- Reduction in heart rate7
- Increase in blood pressure7
- Uterine contraction (in postpartum women)6
Serious Adverse Effects
- Hyperpigmentation7
Contraindications
- Not suitable for individuals with history of cardiovascular disease7
Handling requirements
- Keep away from children and pets
Olympus combines oxytocin and bremelanotide to support sexual wellness in men and women. Oxytocin is a natural hormone that plays a role in bonding, intimacy, and sexual arousal. When taken under the tongue, it can help activate areas of the brain linked to attraction and sexual interest. This may help address feelings of connection and make it easier for the body to respond during sexual activity. Bremelanotide works mainly in the brain. It activates melanocortin 4 receptor (MC4R) that help promote sexual desire and arousal. By activating these receptors, it may help patients reach sexual excitement and support their overall experience. Together, these ingredients work on the brain through different mechanism to help support a healthy sexual response.1-5
IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS
This medication has been compounded (custom-prepared) by a pharmacy. Compounded medications are specially prepared for individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.
This compounded preparation:
- Has not been approved by the FDA
- Has not undergone FDA review for safety, effectiveness, or quality
- Is prepared specifically for you based on your prescriber's order
- Individual outcomes may vary
Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions. Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications. This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.
IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS
This medication has been compounded (custom-prepared) by a pharmacy.
This compounded preparation:
- Has not been approved by the FDA
- Has not undergone FDA review for safety, effectiveness, or quality
- Is prepared specifically for you based on your prescriber's order
- Individual outcomes may vary
Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications.
This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.
- Melis MR, Argiolas A. Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances. Int J Mol Sci. 2021 Sep 26;22(19):10376. doi: 10.3390/ijms221910376. PMID: 34638719; PMCID: PMC8509000.
- Oti T, Sakamoto H. Neuropeptidergic control circuits in the spinal cord for male sexual behaviour: Oxytocin-gastrin-releasing peptide systems. J Neuroendocrinol. 2023 Sep;35(9):e13324. doi: 10.1111/jne.13324. Epub 2023 Jul 29. PMID: 37515539.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild- to- moderate erectile dysfunction. Int J Impot Res. 2004 Feb;16(1):51-9. doi: 10.1038/sj.ijir.3901139. PMID: 14963471.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840; PMCID: PMC6819021.
- Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020 Jul;54(7):684-690. doi: 10.1177/1060028019899152. Epub 2020 Jan 1. PMID: 31893927.
- Oxytocin. Prescribing information. DailyMed. National Library of Medicine. Revised January 12, 2025. Accessed February 26, 2026
- Bremelanotide. Prescribing information. DailyMed. National Library of Medicine. Revised November 13, 2025. Accessed February 26, 2026
- VYLEESI [package insert]. Bridgewater, NJ: Cosette Pharmaceuticals, Inc.; 2024.
Q: How long does it take to see a response?
A: TTypical onset has been observed within 30 minutes after taking. If no effect is seen, you may need to increase your dose up to a max of 1 full tablet per 24 hours as recommended by your prescriber.
Q: Can I use this with other medications?
A:It may be used with other medications. Always consult your prescribing healthcare provider before combining with other medications.
Q: What if I miss a dose?
A: This medication is designed to be used as needed 30 minutes prior to sexual activity. There is no need to take it as a daily dosing unless directed by your prescriber.
Q: Why does bremelanotide cause hyperpigmentation in patients using it for sexual dysfunction?
A:Bremelanotide activates melanocortin receptors that are located in the brain and melanocytes located in the skin. The activation of melanocytes in the skin will increase melanin production and cause darkened patches of skin or gums in some patients. This hyperpigmentation is typically seen on the face, and gums the risk is higher in people with darker skin tones. In some cases, the discoloration may not fully resolve after stopping the medication, so patients are advised to stay within labeled dosing limits and to contact their clinician if they notice new or worsening dark spots while using bremelanotide.8
